Tejas Yuvaraj Suryawanshi

Dr. Tejas Yuvaraj Suryawanshi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2024 in Small
Verified
Journal Article
Closed access
SRSweta Rani
Sweta Rani
RDRahul Kumar Das
Rahul Kumar Das
TSTejas Yuvaraj Suryawanshi
Tejas Yuvaraj Suryawanshi
AJArun Jaiswal
Arun Jaiswal
AMAbhijit Majumder
Abhijit Majumder
Shobha ShuklaShobha Shukla
Shobha Shukla

10 May 2024 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Open access
PDF file
RJRohit Joshi
Rohit Joshi
TSTejas Yuvaraj Suryawanshi
Tejas Yuvaraj Suryawanshi
SMSourav Mukherjee
Sourav Mukherjee
Shobha ShuklaShobha Shukla
Shobha Shukla
AMAbhijit Majumder
Abhijit Majumder
Human mesenchymal stem cells (hMSCs) are multipotent cells that differentiate into adipocytes, chondrocytes, and osteoblasts. Owing to their differentiation potential, hMSCs are among the cells most frequently used for therapeutic applications in tissue engineering and regenerative medicine. However, the number of cells obtained through isolation alone is insufficient for hMSC-based therapies and basic research, which necessitates in vitro expansion. Conventionally, this is often performed on rigid surfaces such as tissue culture plates (TCPs). However, during in vitro expansion, hMSCs lose their proliferative ability and multilineage differentiation potential, rendering them unsuitable for clinical use. Although multiple approaches have been attempted to maintain hMSC stemness during prolonged expansion, finding a suitable culture system remains an unmet need. Recently, a few research groups have shown that hMSCs maintain their stemness over long passages when cultured on soft substrates. In addition, it has been shown that hMSCs cultured on soft substrates have more condensed chromatin and lower levels of histone acetylation compared to those cultured on stiff substrates. Furthermore, it has also been shown that condensing/decondensing chromatin by deacetylation/acetylation can delay replicative senescence in hMSCs during long-term expansion on TCPs. However, the mechanism by which chromatin condensation/decondensation influences nuclear morphology and DNA damage, which are strongly related to the onset of senescence, remains unknown. To answer this question, we cultured hMSCs for long duration in the presence of epigenetic modifiers, histone acetyltransferase inhibitor (HATi), which promotes chromatin condensation by preventing histone acetylation, and histone deacetylase inhibitor (HDACi), which promotes chromatin decondensation, and investigated their effects on various nuclear markers related to senescence. We found that consistent acetylation causes severe nuclear abnormalities, whereas chromatin condensation by deacetylation helps to safeguard the nucleus from damage caused by in vitro expansion.

31 July 2025 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
TSTejas Yuvaraj Suryawanshi
Tejas Yuvaraj Suryawanshi
TAT. Archana
T. Archana
RYRage Yaswanth
Rage Yaswanth
SSSumit Saxena
Sumit Saxena
AMAbhijit Majumder
Abhijit Majumder
Shobha ShuklaShobha Shukla
Shobha Shukla
A schematic showing fs laser-assisted fabrication of micro/nanostructured patterns on cellulose acetate, which were used to guide muscle cell growth, resulting in aligned cells with elongated nuclei, enhanced actin expression and coherency.

13 March 2026 in Immuno
Verified
Journal Article
Open access
PDF file
TSTejas Yuvaraj Suryawanshi
Tejas Yuvaraj Suryawanshi
NRNeha Redkar
Neha Redkar
ASAKANKSHA SHARMA
AKANKSHA SHARMA
JMJyotsna Mishra
Jyotsna Mishra
SSSumit Saxena
Sumit Saxena
Shobha ShuklaShobha Shukla
Shobha Shukla
Neuroinflammation is a central hallmark of numerous neurological disorders, including Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, and spinal cord damage. Its persistent and dysregulated nature not only accelerates neuronal loss but also impedes endogenous repair, posing a major challenge for effective therapeutic intervention. Recent advances in nanobiotechnology have opened transformative opportunities to modulate neuroinflammation with unprecedented precision while simultaneously supporting neural regeneration. This review highlights emerging nanomaterial-based strategies including lipid-based, polymeric, inorganic nanoparticles designed to traverse the blood–brain barrier (BBB), deliver anti-inflammatory agents, modulate immune cell behavior, and attenuate glial activation. Extending beyond nanoparticle-based delivery systems, recent advances also emphasize the integration of nanomaterials into biomimetic architectures to provide structural and functional cues for neural repair. We further summarize how these functional nanostructured scaffolds, such as extracellular matrix (ECM) mimetic, nanofibrous and conductive hydrogels, are being leveraged in neural tissue engineering to direct stem cell fate, promote axonal outgrowth, and rebuild damaged neuroarchitectures. Moreover, pharmacokinetics, biodistribution, safety, clinical trials, regulatory considerations and limitations of nanotherapeutics in neurodegenerative diseases are discussed. By outlining the current progress, mechanistic insights, and translational challenges, this review underscores the potential of nanobiotechnology-enabled therapeutics to revolutionize the treatment of neuroinflammatory conditions and advance next-generation neural repair technologies.